The investment strengthens Groq's role in the American AI Stack, delivering fast, affordable compute worldwide.
MOUNTAIN VIEW, Calif., Sept. 17, 2025 /PRNewswire/ -- Groq, the pioneer in AI inference, today announced $750 million in new financing at a post-money valuation of $6.9 billion. The round was led by Disruptive with significant investment from Blackrock, Neuberger Berman, Deutsche Telekom Capital Partners and a large US-based West Coast mutual fund manager. The raise also included continued support from Samsung, Cisco, D1, Altimeter, 1789 Capital and Infinitum.
Groq powers more than two million developers and Fortune 500 companies with fast, affordable compute and is growing its presence globally, building on existing data centers in North America, Europe, and the Middle East.
"Inference is defining this era of AI, and we're building the American infrastructure that delivers it with high speed and low cost." — Jonathan Ross, Groq Founder and CEO
The White House recently issued an executive order promoting the export of the American AI Technology Stack, emphasizing the global deployment of US-origin AI technology. Groq is playing a central role, with their American-built inference infrastructure already powering developers and enterprises worldwide.
Disruptive, a Dallas-based growth investment firm, has backed some of the most transformative and successful companies in the last decade, including large investments in Palantir, Airbnb, Spotify, Shield AI, Hims, Databricks, Stripe, Slack and many other AI leaders and AI adjacent businesses. Disruptive has invested nearly $350 million in Groq.
"As AI expands, the infrastructure behind it will be as essential as the models themselves," said Alex Davis, Founder, Chairman, and CEO of Disruptive. "Groq is building that foundation, and we couldn't be more excited to partner with Jonathan and his team in this next chapter of explosive growth."
About Groq
Groq is the inference infrastructure that powers AI with the speed and cost it requires. Founded in 2016, the company created the LPU and GroqCloud to ensure compute is faster and more affordable. Today, Groq is a key part of the American AI Stack and trusted by more than two million developers and many of the world's leading Fortune 500 companies.
Groq Media Contact: pr-media@groq.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Groq Raises $750 Million as Inference Demand Surges
|
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.
A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.
"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings," said Dr. Samantha South, CEO, Patrys.
The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina's partnership with Patrys, reflecting BioCina's commitment to supporting clients at every stage of their product development journey.
"We are thrilled to support Patrys' journey for RLS-2201. BioCina's 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs - improving patient outcomes," said Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.
BioCina's capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world's most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.
For more information, visit www.biocina.com
About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys' deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.
Patrys' CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.
For more information, visit www.patrys.com
Media Contact
media@biocina.com
Photo - https://mma.prnasia.com/media2/2933870/patrys_release_image_250225_8335.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2346937/BioCina_New_Logo.jpg?p=medium600
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.
A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.
"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings," said Dr. Samantha South, CEO, Patrys.
The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina's partnership with Patrys, reflecting BioCina's commitment to supporting clients at every stage of their product development journey.
"We are thrilled to support Patrys' journey for RLS-2201. BioCina's 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs - improving patient outcomes," said Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.
BioCina's capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world's most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.
For more information, visit www.biocina.com
About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys' deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.
Patrys' CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.
For more information, visit www.patrys.com
Media Contact
media@biocina.com
Photo - https://mma.prnasia.com/media2/2933870/patrys_release_image_250225_8335.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2346937/BioCina_New_Logo.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
